274 Results

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Levine
    Levine
  3. Tallman
    Tallman
  4. Rampal
    Rampal
  5. Patel
    Patel
  6. Chung
    Chung
  7. Taylor
    Taylor
  8. Park
    Park
  9. Diamond
    Diamond
  10. Hyman
    Hyman

Groups

  1. Adult Leukemia (274)
  2. Center for Hematologic Malignancies (274)
  3. Department of Medicine (274)
  4. Executive Committee, Center for Hematologic Malignancies (274)
  5. GSK Faculty (274)
  6. Hematologic Malignancies, Division of (274)
  7. Human Oncology and Pathogenesis Program (274)
  8. Tow Center for Developmental Oncology (TCDO) (274)
  9. Sloan Kettering Institute Postdocs (95)
  10. Epidemiology and Biostatistics (47)
  1. "Omar Abdel-Wahab"
  2. "Adult Leukemia"
  3. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (146)
  2. Meeting Abstract (121)
  3. Book Section (4)
  4. Editorial (1)
  5. Research Letter (1)
  6. Review (1)
Groups
  1. Adult Leukemia (274)
  2. Center for Hematologic Malignancies (274)
  3. Department of Medicine (274)
  4. Executive Committee, Center for Hematologic Malignancies (274)
  5. GSK Faculty (274)
  6. Hematologic Malignancies, Division of (274)

More Groups

People
  1. Omar Abdel-Wahab (274)
  2. Ross Levine (165)
  3. Martin Tallman (68)
  4. Raajit Rampal (63)
  5. Jay Patel (40)
  6. Benjamin Durham (34)

More People

Years
  1. 2024 (1)
  2. 2023 (13)
  3. 2022 (15)
  4. 2021 (10)
  5. 2020 (19)
  6. 2019 (15)

More Years

Publications
  1. Blood (109)
  2. Leukemia (16)
  3. Cancer Cell (10)
  4. Haematologica (9)
  5. Cancer Discovery (7)
  6. Cancer Research (7)

More Publications

Publishers
  1. American Society of Hematology (113)
  2. Nature Publishing Group (42)
  3. American Association for Cancer Research (15)
  4. Cell Press (13)
  5. Ferrata Storti Foundation (9)
  6. American Society of Clinical Oncology (7)

More Publishers

Results (274)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Meeting Abstract

    Bewersdorf, J. P.; Chandhok, N. S.; Watts, J. M.; Derkach, A.; Abdel-Wahab, O.; Stein, E. M.; Taylor, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Research Letter

    Bewersdorf, J. P.; Stahl, M.; Taylor, J.; Mi, X.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Lu, S. X.; Bourcier, J.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Journal Article

    Ptashkin, R. N.; Ewalt, M. D.; Jayakumaran, G.; Kiecka, I.; Bowman, A. S.; Yao, J. J.; Casanova, J.; Lin, Y. T. D.; Petrova-Drus, K.; Mohanty, A. S.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Characteristics and prognostic impact of IDH mutations in AML: A COG, SWOG, and ECOG analysis
    Journal Article

    Zarnegar-Lumley, S.; Alonzo, T. A.; Gerbing, R. B.; Othus, M.; Sun, Z.; Ries, R. E.; Wang, J.; Leonti, A.; Kutny, M. A.; Ostronoff, F.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
    Journal Article

    McCarter, J. G. W.; Nemirovsky, D.; Famulare, C. A.; Farnoud, N.; Mohanty, A. S.; Stone-Molloy, Z. S.; Chervin, J.; Ball, B. J.; Epstein-Peterson, Z. D.; Arcila, M. E.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save